阿扎胞苷联合低剂量HAG方案治疗老年急性髓系白血病临床研究  

Efficacy and safety of azacytidine combined with low-dose HAG regimen in treatment of newly diagnosed elderly acute myeloid leukemia patients

作　　者：王东海 刘杰 李志华 张玲 罗洁 张晓东 庞明禹 陈琛 刘美晨 纪超宇 WANG Donghai;LIU Jie;LI Zhihua;ZHANG Ling;LUO Jie;ZHANG Xiaodong;PANG Mingyu;CHEN Chen;LIU Meichen;JI Chaoyu(National Medicine Tongmei General Hospital,Datong 037003,China)

机构地区：[1]国药同煤总医院,山西大同037003

出　　处：《临床医药实践》2025年第1期31-33,37,共4页Proceeding of Clinical Medicine

摘　　要：目的:探讨阿扎胞苷(AZA)联合低剂量HAG方案治疗老年急性髓系白血病(AML)患者的效果。方法:选取2021年9月—2023年9月收治的老年急性髓系白血病患者24例,随机分为治疗组和对照组,每组12例。治疗组采用阿扎胞苷联合低剂量HAG方案(AZA-HAG)治疗,对照组采用地西他滨联合CAG方案(DAC-CAG)治疗,评价两组治疗效果。结果:治疗一个疗程后治疗组总缓解率(OR)为66.7%,对照组OR为58.3%,两组比较,差异无统计学意义(P>0.05)。治疗组平均生存时间11.0个月,对照组平均生存时间9.5个月,两组总生存期(OS)比较,差异无统计学意义(P>0.05)。治疗组发生4度骨髓抑制7例(58.3%),骨髓抑制恢复天数(13.50±2.84)d;对照组12例均发生4度骨髓抑制(100.0%),骨髓抑制恢复天数(17.67±2.23)d,两组比较,差异有统计学统计学意义(P<0.05)。结论:阿扎胞苷联合低剂量HAG方案治疗不适合强化疗的新诊断老年AML患者疗效肯定,且安全性更高,经济费用更低。Objective:To evaluate the efficacy and safety of azacitidine(AZA)combined with HAG regimen in the treatment of newly diagnosed elderly acute myeloid leukemia(AML)patients.Methods:Twenty-four newly diagnosed elderly AML patients ineligible for intensive chemotherapy from September 2021 to September 2023 in the Sinopharm Tongmei General hospital were prospectively enrolled in this study.They were randomly divided into treatment group and control group.The treatment group was treated with azacytidine combined with low-dose HAG regimen(AZA-HAG),while the control group was treated with decitabine combined with CAG regimen(DAC-CAG).The therapeutic effects of the two groups were evaluated.Results:After one course of treatment,the total remission rate(OR)of treatment group was 66.7%,and that of control group was 58.3%,and there was no significant difference between the two groups(P>0.05).The average survival time of treatment group was 11.0 months,and that of control group was 9.5 months.The overall survival(OS)was no significant difference between the two groups(P>0.05).In the treatment group,there were 7 cases(58.3%)with 4-degree bone marrow suppression,and the recovery days of bone marrow suppression were(13.50±2.84)d;In the control group,all 12 cases suffered from 4-degree bone marrow suppression(100.0%),and the days of recovery from bone marrow suppression were(17.67±2.23)d,and the difference was statistically significant(P<0.05).Conclusion:Azacitidine combined with low-dose HAG regimen is effective in the treatment of newly diagnosed elderly AML patients who are not eligible for intensive chemotherapy,and it is safe and cost-effective.

关 键 词：急性髓系白血病 老年 阿扎胞苷 HAG方案 治疗效果 

分 类 号：R735[医药卫生—肿瘤]